Norge -
norsk -
Statens legemiddelverk
bosentan sandoz 125 mg
sandoz - københavn - bosentanmonohydrat - tablett, filmdrasjert - 125 mg
Norge -
norsk -
Statens legemiddelverk
bosentan sandoz 62.5 mg
sandoz - københavn - bosentanmonohydrat - tablett, filmdrasjert - 62.5 mg
Norge -
norsk -
Statens legemiddelverk
hypoloc 5 mg
menarini international o.l. s.a. - nebivololhydroklorid - tablett - 5 mg
Norge -
norsk -
Statens legemiddelverk
bosentan aurobindo 125 mg
aurobindo pharma (malta) limited - floriana - bosentanmonohydrat - tablett, filmdrasjert - 125 mg
Norge -
norsk -
Statens legemiddelverk
bosentan aurobindo 62.5 mg
aurobindo pharma (malta) limited - floriana - bosentanmonohydrat - tablett, filmdrasjert - 62.5 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
ayvakyt
blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinal stromal tumors - andre cytostatika, protein kinase hemmere - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.
Norge -
norsk -
Statens legemiddelverk
bosentan cipla 125 mg
cipla europe nv - bosentanmonohydrat - tablett, filmdrasjert - 125 mg
Norge -
norsk -
Statens legemiddelverk
bosentan cipla 62.5 mg
cipla europe nv - bosentanmonohydrat - tablett, filmdrasjert - 62.5 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
Norge -
norsk -
Statens legemiddelverk
sunitinib sandoz 12.5 mg
sandoz - københavn - sunitinib - kapsel, hard - 12.5 mg